NCT07400523 2026-04-17
Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting
Clinical Trials
7 trialsNCT05664893 2026-04-15
CALHYS
Centre Antoine Lacassagne
Phase 1/2 Withdrawn
NCT04920708 2026-04-14
FAIM
Royal Marsden NHS Foundation Trust
Phase 2 Active not recruiting
NCT07164976 2026-04-13
Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer
Nagoya City University
Phase 1/2 Recruiting
NCT05467891 2026-04-08
RaPhLRR
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT07487129 2026-03-23
Clinical and P
Beni-Suef University
Phase 4 Completed
NCT05843253 2026-03-20
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Phase 2 Recruiting